Cargando…
Mavrilimumab for severe COVID-19 – Authors' reply
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837188/ https://www.ncbi.nlm.nih.gov/pubmed/33521663 http://dx.doi.org/10.1016/S2665-9913(20)30308-8 |
| _version_ | 1783642910851334144 |
|---|---|
| author | De Luca, Giacomo Cavalli, Giulio Campochiaro, Corrado Della-Torre, Emanuel Dagna, Lorenzo |
| author_facet | De Luca, Giacomo Cavalli, Giulio Campochiaro, Corrado Della-Torre, Emanuel Dagna, Lorenzo |
| author_sort | De Luca, Giacomo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7837188 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78371882021-01-26 Mavrilimumab for severe COVID-19 – Authors' reply De Luca, Giacomo Cavalli, Giulio Campochiaro, Corrado Della-Torre, Emanuel Dagna, Lorenzo Lancet Rheumatol Correspondence Elsevier Ltd. 2020-11 2020-09-05 /pmc/articles/PMC7837188/ /pubmed/33521663 http://dx.doi.org/10.1016/S2665-9913(20)30308-8 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence De Luca, Giacomo Cavalli, Giulio Campochiaro, Corrado Della-Torre, Emanuel Dagna, Lorenzo Mavrilimumab for severe COVID-19 – Authors' reply |
| title | Mavrilimumab for severe COVID-19 – Authors' reply |
| title_full | Mavrilimumab for severe COVID-19 – Authors' reply |
| title_fullStr | Mavrilimumab for severe COVID-19 – Authors' reply |
| title_full_unstemmed | Mavrilimumab for severe COVID-19 – Authors' reply |
| title_short | Mavrilimumab for severe COVID-19 – Authors' reply |
| title_sort | mavrilimumab for severe covid-19 – authors' reply |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837188/ https://www.ncbi.nlm.nih.gov/pubmed/33521663 http://dx.doi.org/10.1016/S2665-9913(20)30308-8 |
| work_keys_str_mv | AT delucagiacomo mavrilimumabforseverecovid19authorsreply AT cavalligiulio mavrilimumabforseverecovid19authorsreply AT campochiarocorrado mavrilimumabforseverecovid19authorsreply AT dellatorreemanuel mavrilimumabforseverecovid19authorsreply AT dagnalorenzo mavrilimumabforseverecovid19authorsreply |